A Clinical Trial of Retinal Gene Therapy for X-linked Ret... | NCT03116113 | Trialant
NCT03116113
Sponsor
Biogen
Status
Completed
Last Update Posted
Jan 18, 2024Actual
Enrollment
50Actual
Phase
Phase 1Phase 2
Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIIB112
Countries
United States
United Kingdom
Protocol Section
Identification Module
NCT ID
Results Section
Participant Flow Module
Pre-assignment Details
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Derived Section
Miscellaneous Info Module
Version Holder
NCT03116113
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
274RP101
Secondary IDs
ID
Type
Description
Link
2016-003852-60
EudraCT Number
Brief Title
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
Official Title
A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)
Acronym
XIRIUS
Organization
BiogenINDUSTRY
Status Module
Record Verification Date
Dec 2023
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Mar 8, 2017Actual
Primary Completion Date
Nov 18, 2020Actual
Completion Date
Nov 18, 2020Actual
First Submitted Date
Mar 29, 2017
First Submission Date that Met QC Criteria
Apr 13, 2017
First Posted Date
Apr 14, 2017Actual
Results Waived
Not provided
Results First Submitted Date
Nov 16, 2023
Results First Submitted that Met QC Criteria
Dec 22, 2023
Results First Posted Date
Jan 18, 2024Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Nov 17, 2021
Certification/Extension First Submitted that Passed QC Review
Nov 17, 2021
Certification/Extension First Posted Date
Nov 22, 2021Actual
Last Update Submitted Date
Dec 22, 2023
Last Update Posted Date
Jan 18, 2024Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
BiogenINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).
Detailed Description
This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.
Conditions Module
Conditions
X-Linked Retinitis Pigmentosa
Keywords
XLRP
Ophthalmology
Gene Therapy
Retinitis Pigmentosa GTPase Regulator (RPGR)
AAV8
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
50Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Part 1: BIIB112 Dose 1
Experimental
Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 1: BIIB112 Dose 2
Experimental
Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 1: BIIB112 Dose 3
Experimental
Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 1: BIIB112 Dose 4
Experimental
Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 1: BIIB112 Dose 5
Experimental
Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 1: BIIB112 Dose 6
Experimental
Interventions
Name
Type
Description
Arm Group Labels
Other Names
BIIB112
Biological
Administered as specified in the treatment arm.
Part 1: BIIB112 Dose 1
Part 1: BIIB112 Dose 2
Part 1: BIIB112 Dose 3
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
DLTs are defined as any of the following events considered to be related to study drug: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within <24 hours} of the surgery); Vitreous inflammation, vitritis (>Grade 3 using standardized Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
Up to Month 24
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as the AEs starting or worsening on or after the day of the first surgery.
Day 0 (surgery) in Part 1 of the study up to 24 months
Part 2: Percentage of Study Eyes With ≥7 Decibels (dB) Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0', or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Secondary Outcomes
Measure
Description
Time Frame
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Key Inclusion Criteria:
Part 1:
Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation).
Participant with active disease clinically visible within the macular region in both eyes.
Part 2:
- Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB.
Key exclusion Criteria:
Parts 1 and 2:
Participant with history of amblyopia in either eye.
Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A, Wood LJ, Salvetti AP, Fischer MD, Aylward JW, Barnard AR, Jolly JK, Luo E, Lujan BJ, Ong T, Girach A, Black GCM, Gregori NZ, Davis JL, Rosa PR, Lotery AJ, Lam BL, Stanga PE, MacLaren RE. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020 Mar;26(3):354-359. doi: 10.1038/s41591-020-0763-1. Epub 2020 Feb 24.
A total of 50 participants with X-Linked Retinitis Pigmentosa (XLRP) were enrolled in the study (18 participants in Part 1 and 32 participants in Part 2). Of these, 47 participants completed the study (18 participants in Part 1 and 29 in Part 2).
Recruitment Details
Participants were enrolled at investigational sites in the United Kingdom (UK) and the United States (US) from 08 March 2017 to 18 November 2020.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vector genomes {vg} ) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG006
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
FG007
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
FG008
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Periods
Title
Milestones
Reasons Not Completed
Part 1 (Day 0 up to Month 24)
Type
Comment
Milestone Data
STARTED
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0033 subjects
FG004
COMPLETED
FG0003 subjects
FG0013 subjects
FG0023 subjects
FG0033 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Part 2 (Month 25 up to Month 36)
Type
Comment
Milestone Data
STARTED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG003
Baseline Characteristics Module
Baseline Analysis Population Description
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG001
Part 1: BIIB112 Dose 2
Denominators
Units
Counts
Participants
BG000
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Outcome Measures Module
Outcome Measures
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
DLTs are defined as any of the following events considered to be related to study drug: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within <24 hours} of the surgery); Vitreous inflammation, vitritis (>Grade 3 using standardized Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Count of Participants
Participants
Up to Month 24
ID
Title
Description
Adverse Events Module
Frequency Threshold
5
Time Frame
Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Description
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
Biological: BIIB112
Part 2: BIIB112 High Dose
Experimental
Participants will receive a single high dose of BIIB112 by sub-retinal injection.
Biological: BIIB112
Part 2: BIIB112 Low Dose
Experimental
Participants will receive a single low dose of BIIB112 by sub-retinal injection.
Biological: BIIB112
Part 2: Untreated Group
No Intervention
Participants will receive no intervention to allow for a controlled comparison.
Part 1: BIIB112 Dose 4
Part 1: BIIB112 Dose 5
Part 1: BIIB112 Dose 6
Part 2: BIIB112 High Dose
Part 2: BIIB112 Low Dose
AAV8-RPGR
Month 12
Part 2: Number of Participants With TEAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as AEs starting on or after the day of the first surgery.
Day 0 (surgery) in Part 2 of the study up to 12 months
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participants using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in LLVA.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Central Ellipsoid Area
Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central ellipsoid area.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central horizontal ellipsoid width.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Fundus Autofluoroscence was used to assess the total area of preserved autofluoroscence. Areas of preserved AF were identified as well-demarcated regions of relative hyper autofluorescence (hyper AF) compared with the background areas of surrounding atrophy. A negative change from baseline indicates a decline in total area of preserved autofluoroscence.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Fundus Autofluoroscence was used to assess the distance from FC to nearest border of preserved autofluoroscence. A negative change from baseline indicates a decline in the total area of preserved autofluoroscence.
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Baseline, Months 6, 12, and 24
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF =number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Baseline, Months 6, 12, and 24
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change in CS was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Participants read the letters, starting with the highest contrast, until they were unable to read two or three letters in a single group. Each group had three letters of the same contrast level, so there were three trials per contrast level. Participant is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the participant's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = [(total letters correct - 3) x 0.05].
Baseline, Months 3, 6, 12, and 24
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Months 1, 2, 3, 6, and 9
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
Months 1, 2, 3, 6, 9, and 12
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Mean Sensitivity in center grid was defined as the mean in dB of the 16 points located in the center of the grid. Here negative values indicate a decline in retinal sensitivity.
Baseline, Months 1, 2, 3, 6, 9, and 12
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean ensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Baseline, Months 1, 2, 3, 6, 9, and 12
Part 2: Change From Baseline in BCVA Reported as Letters
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in BCVA.
Baseline, Months 1, 2, 3, 6, 9, and 12
Part 2: Change From Baseline in Mean LLVA Reported as Letters
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in LLVA.
Baseline, Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
Months 1, 2, 3, 6, 9, and 12
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
Months 1, 3, 6, 9, and 12
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in the volume of 30-degree hill vision.
Baseline, Months 3, 6, and 12
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of full field hill vision.
Baseline, Months 3, 6, and 12
Miami
Florida
33136
United States
Research Site
Portland
Oregon
97239
United States
Research Site
Philadelphia
Pennsylvania
19104
United States
Research Site
Dallas
Texas
75231
United States
Research Site
Manchester
United Kingdom
Research Site
Oxford
United Kingdom
Research Site
Southampton
United Kingdom
Derived
Raji S, Taylor LJ, Josan AS, MacLaren RE, Cehajic-Kapetanovic J. Early-Onset Cone Photoreceptor Degeneration Is Associated With High Myopia in RPGR-Related Retinal Dystrophy. J Ophthalmol. 2025 Jun 11;2025:4244740. doi: 10.1155/joph/4244740. eCollection 2025.
Lam BL, Pennesi ME, Kay CN, Panda S, Gow JA, Zhao G, MacLaren RE; XIRIUS Study Group. Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study. Ophthalmology. 2024 Sep;131(9):1083-1093. doi: 10.1016/j.ophtha.2024.02.023. Epub 2024 Feb 28.
von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, Lotery AJ, Jalil A, Lam BL, MacLaren RE; XIRIUS Part 1 Study GroupXOLARIS Study Group. Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations. JAMA Ophthalmol. 2023 Mar 1;141(3):275-283. doi: 10.1001/jamaophthalmol.2022.6254.
3 subjects
FG0053 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
3 subjects
FG0053 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
0 subjects
FG0040 subjects
FG0050 subjects
FG0069 subjects
FG00711 subjects
FG00812 subjects
COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0069 subjects
FG00710 subjects
FG00810 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0071 subjects
FG0082 subjects
Type
Comment
Reasons
Withdrew due to Coronavirus 2019COVID-19
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0071 subjects
FG0082 subjects
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG006
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
BG007
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG008
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
BG009
Total
Total of all reporting groups
3
BG0013
BG0023
BG0033
BG0043
BG0053
BG0069
BG00711
BG00812
BG00950
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00036.3± 6.35
BG00134.3± 10.69
BG00230.0± 2.65
BG00333.3± 14.57
BG00425.0± 5.00
BG00532.3± 15.31
BG00633.7± 13.83
BG00730.6± 8.83
BG00826.8± 7.11
BG00930.7± 9.75
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
Male
BG0003
BG0013
BG0023
BG0033
BG004
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0010
BG0020
BG0030
BG0040
BG0051
BG0062
BG0073
BG0085
BG00911
Not Hispanic or Latino
BG0003
BG0013
BG0023
BG0033
BG004
Unknown or Not Reported
BG0000
BG0010
BG0020
BG0030
BG004
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Race
Title
Measurements
Asian
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0071
BG0080
BG0091
Black or African American
BG0000
BG0010
BG0020
BG0030
BG004
White
BG0003
BG0013
BG0023
BG0033
BG004
More than one race
BG0000
BG0010
BG0020
BG0030
BG004
Other
BG0000
BG0010
BG0020
BG0030
BG004
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG0033
OG0043
OG0053
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
Primary
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as the AEs starting or worsening on or after the day of the first surgery.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Count of Participants
Participants
Day 0 (surgery) in Part 1 of the study up to 24 months
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Title
Measurements
OG0003
OG0013
OG0023
OG003
Primary
Part 2: Percentage of Study Eyes With ≥7 Decibels (dB) Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0', or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Intent-to-treat (ITT) analysis set included all participants that were randomized under the 3-arm randomization schedules. "Overall number of participants analyzed" signifies the number of participants with data available for analysis of this outcome measure.
Posted
Number
80% Confidence Interval
percentage of study eyes
Month 12
Study eyes
Study eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG0018
OG0028
Study eyes
OG000
Title
Denominators
Categories
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00137.5(14.7 to 65.5)
OG00225.0(6.9 to 53.8)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Fisher's Exact-Boschloo test
=0.3181
Superiority
OG000
OG002
Fisher's Exact-Boschloo test
=0.5177
Primary
Part 2: Number of Participants With TEAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as AEs starting on or after the day of the first surgery.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Count of Participants
Participants
Day 0 (surgery) in Part 2 of the study up to 12 months
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00111
OG00212
Title
Denominators
Categories
Title
Measurements
OG0005
OG00111
OG00212
Secondary
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
95% Confidence Interval
percentage of study eyes
Months 1, 3, 6, 9, 12, 18, and 24
study eyes
study eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0012
OG0023
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
95% Confidence Interval
percentage of study eyes
Months 1, 3, 6, 9, 12, 18, and 24
study eyes
study eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0012
OG0023
OG003
Title
Denominators
Categories
Month 1
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0012
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0012
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participants using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Mean
Standard Deviation
letters
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in LLVA.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Mean
Standard Deviation
letters
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single Dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single Dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
Posted
Number
95% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0022
OG003
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Central Ellipsoid Area
Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central ellipsoid area.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
square millimeters (mm^2)
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central horizontal ellipsoid width.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
Microns
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Fundus Autofluoroscence was used to assess the total area of preserved autofluoroscence. Areas of preserved AF were identified as well-demarcated regions of relative hyper autofluorescence (hyper AF) compared with the background areas of surrounding atrophy. A negative change from baseline indicates a decline in total area of preserved autofluoroscence.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
mm^2
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0001
OG0010
OG0021
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Fundus Autofluoroscence was used to assess the distance from FC to nearest border of preserved autofluoroscence. A negative change from baseline indicates a decline in the total area of preserved autofluoroscence.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
mm^2
Baseline, Months 1, 3, 6, 9, 12, 18, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0002
OG0011
OG0021
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 6, 12, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0020
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF =number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 6, 12, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single Dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single Dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single Dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0000
OG0010
OG0020
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change in CS was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Participants read the letters, starting with the highest contrast, until they were unable to read two or three letters in a single group. Each group had three letters of the same contrast level, so there were three trials per contrast level. Participant is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the participant's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = [(total letters correct - 3) x 0.05].
Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
Score on scale
Baseline, Months 3, 6, 12, and 24
eyes
eyes
ID
Title
Description
OG000
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0003
OG0013
OG0023
OG003
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG003
Secondary
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of study eyes
Months 1, 2, 3, 6, and 9
study eyes
study eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
study eyes
OG000
Title
Denominators
Categories
Month 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
study eyesOG000
Secondary
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of study eyes
Months 1, 2, 3, 6, 9, and 12
study eyes
study eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
study eyes
OG000
Title
Denominators
Categories
Month 1
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00160.0(35.4 to 81.2)
OG00240.0(18.8 to 64.6)
Month 2
Secondary
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Mean Sensitivity in center grid was defined as the mean in dB of the 16 points located in the center of the grid. Here negative values indicate a decline in retinal sensitivity.
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '< 0', '0' or a positive integer. The point labelled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean ensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Change From Baseline in BCVA Reported as Letters
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in BCVA.
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
letters
Baseline, Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Change From Baseline in Mean LLVA Reported as Letters
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in LLVA.
ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
letters
Baseline, Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. "Number analyzed" signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 2, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Number
80% Confidence Interval
percentage of eyes
Months 1, 3, 6, 9, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0009
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in the volume of 30-degree hill vision.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 3, 6, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0008
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
Secondary
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of full field hill vision.
ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Posted
Mean
Standard Deviation
dBs
Baseline, Months 3, 6, and 12
eyes
eyes
ID
Title
Description
OG000
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
OG001
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
OG002
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
Units
Counts
Participants
OG0008
OG00110
OG00210
eyes
OG000
Title
Denominators
Categories
Baseline: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG000
0
3
1
3
3
3
EG001
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
3
1
3
3
3
EG002
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
3
0
3
3
3
EG003
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
3
0
3
3
3
EG004
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
3
1
3
3
3
EG005
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
3
2
3
3
3
EG006
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
0
9
1
9
5
9
EG007
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
11
3
11
11
11
EG008
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
0
12
5
12
12
12
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Noninfective retinitis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Retinal detachment
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Subretinal fluid
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0083 affected12 at risk
Visual acuity reduced
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Visual impairment
Eye disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Food poisoning
Gastrointestinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Nephrolithiasis
Renal and urinary disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Appendicitis
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Urinary tract infection
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Hypertension
Vascular disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Tooth extraction
Surgical and medical procedures
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Multiple allergies
Immune system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Seasonal allergy
Immune system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Bronchiectasis
Respiratory, thoracic and mediastinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0062 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Depression
Psychiatric disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Blood bilirubin increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Blood creatinine increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Blood glucose increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Blood triglycerides increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Intraocular pressure decreased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Intraocular pressure increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0021 affected3 at risk
EG0031 affected3 at risk
EG0041 affected3 at risk
EG0052 affected3 at risk
EG0061 affected9 at risk
EG0076 affected11 at risk
EG0085 affected12 at risk
Lymphocyte count decreased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Neutrophil count increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0084 affected12 at risk
Visual field tests abnormal
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Vitamin d decreased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
White blood cell count increased
Investigations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Corneal abrasion
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Dysphotopsia
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Eye contusion
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Muscle rupture
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Ocular procedural complication
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0082 affected12 at risk
Post procedural discomfort
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Post procedural inflammation
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Post-traumatic neck syndrome
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Post-traumatic pain
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Procedural pain
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Skin laceration
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Suture related complication
Injury, poisoning and procedural complications
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0085 affected12 at risk
Atrial fibrillation
Cardiac disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Palpitations
Cardiac disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Dizziness
Nervous system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Headache
Nervous system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0081 affected12 at risk
Paraesthesia
Nervous system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Tunnel vision
Nervous system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Anterior chamber inflammation
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0012 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0080 affected12 at risk
Asthenopia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Blepharitis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Blindness transient
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Cataract
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0061 affected9 at risk
EG0073 affected11 at risk
EG0083 affected12 at risk
Cataract subcapsular
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0081 affected12 at risk
Choroidal detachment
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Chromatopsia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Conjunctival haemorrhage
Eye disorders
MedDRA23.1
Systematic Assessment
EG0003 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0076 affected11 at risk
EG0089 affected12 at risk
Conjunctival hyperaemia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0081 affected12 at risk
Conjunctival irritation
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Conjunctival oedema
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Corneal deposits
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Cystoid macular oedema
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0084 affected12 at risk
Delayed light adaptation
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Detachment of macular retinal pigment epithelium
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Diplopia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Dry eye
Eye disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Dyschromatopsia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Eye inflammation
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0031 affected3 at risk
EG0042 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Eye pain
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0082 affected12 at risk
Eye pruritus
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Eyelid oedema
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Eyelid ptosis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Foreign body sensation in eyes
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Hypotony of eye
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Iridocyclitis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Iritis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0082 affected12 at risk
Lacrimation increased
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0082 affected12 at risk
Lenticular pigmentation
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Macular fibrosis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Maculopathy
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Metamorphopsia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0084 affected12 at risk
Noninfective retinitis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0041 affected3 at risk
EG0053 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0083 affected12 at risk
Ocular discomfort
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0082 affected12 at risk
Ocular hypertension
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Photophobia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0082 affected12 at risk
Posterior capsule opacification
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Retinal artery embolism
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Retinal cyst
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Retinal degeneration
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Retinal deposits
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0082 affected12 at risk
Retinal fovea disorder
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Retinal haemorrhage
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Retinal infiltrates
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Retinal oedema
Eye disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Retinal tear
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0082 affected12 at risk
Retinal thickening
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Retinoschisis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Scleritis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Subretinal fluid
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0083 affected12 at risk
Vision blurred
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0031 affected3 at risk
EG0041 affected3 at risk
EG0051 affected3 at risk
EG0061 affected9 at risk
EG0071 affected11 at risk
EG0084 affected12 at risk
Visual acuity reduced
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0083 affected12 at risk
Visual impairment
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0083 affected12 at risk
Vitreal cells
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0084 affected12 at risk
Vitreous detachment
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Vitritis
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0085 affected12 at risk
Dyspepsia
Gastrointestinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Nausea
Gastrointestinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0082 affected12 at risk
Stomatitis
Gastrointestinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Vomiting
Gastrointestinal disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0081 affected12 at risk
Acne
Skin and subcutaneous tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0083 affected12 at risk
Erythema
Skin and subcutaneous tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Night sweats
Skin and subcutaneous tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
Rash
Skin and subcutaneous tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Urticaria
Skin and subcutaneous tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Chondrocalcinosis pyrophosphate
Musculoskeletal and connective tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0011 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Bursitis infective
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Conjunctivitis
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Ear infection
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Gastroenteritis
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Hypopyon
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Infected dermal cyst
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Influenza
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Lower respiratory tract infection
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Nasopharyngitis
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0021 affected3 at risk
EG0030 affected3 at risk
EG0041 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0080 affected12 at risk
Upper respiratory tract infection
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0072 affected11 at risk
EG0080 affected12 at risk
Urinary tract infection
Infections and infestations
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0061 affected9 at risk
EG0071 affected11 at risk
EG0080 affected12 at risk
Eustachian tube dysfunction
Ear and labyrinth disorders
MedDRA23.1
Systematic Assessment
EG0001 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0080 affected12 at risk
Aniseikonia
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0071 affected11 at risk
EG0081 affected12 at risk
Anterior chamber cell
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0051 affected3 at risk
EG0060 affected9 at risk
EG0075 affected11 at risk
EG0086 affected12 at risk
Anterior chamber flare
Eye disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0083 affected12 at risk
Visual field defect
Nervous system disorders
MedDRA23.1
Systematic Assessment
EG0000 affected3 at risk
EG0010 affected3 at risk
EG0020 affected3 at risk
EG0030 affected3 at risk
EG0040 affected3 at risk
EG0050 affected3 at risk
EG0060 affected9 at risk
EG0070 affected11 at risk
EG0081 affected12 at risk
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Our agreement is subject to confidentiality but generally, the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor's Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of the Sponsor's intellectual property contained in the proposed publication.
3
BG0053
BG0069
BG00711
BG00812
BG00950
3
BG0052
BG0067
BG0078
BG0087
BG00939
0
BG0050
BG0060
BG0070
BG0080
BG0090
0
BG0050
BG0060
BG0071
BG0080
BG0091
3
BG0053
BG0066
BG0079
BG00812
BG00945
0
BG0050
BG0061
BG0070
BG0080
BG0091
0
BG0050
BG0062
BG0070
BG0080
BG0092
3
OG0043
OG0053
3
OG0043
OG0053
9
OG0018
OG0028
Superiority
3
OG0043
OG0053
study eyes
OG0003
OG0012
OG0023
OG0033
OG0043
OG0053
3
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG0043
study eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG002100.0(29.2 to 100.0)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
Month 3
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 6
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 9
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 12
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00233.3(0.8 to 90.6)
OG003
Month 18
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 24
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0011
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 97.5)
OG00233.3(0.8 to 90.6)
OG003
3
OG0043
OG0053
study eyes
OG0003
OG0012
OG0023
OG0033
OG0043
OG0053
3
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG0043
study eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG002100.0(29.2 to 100.0)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
Month 3
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 6
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG002100.0(29.2 to 100.0)
OG003
Month 9
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 84.2)
OG00266.7(9.4 to 99.2)
OG003
Month 12
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG00150.0(1.3 to 98.7)
OG00266.7(9.4 to 99.2)
OG003
Month 18
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
study eyesOG0003
study eyesOG0012
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG00150.0(1.3 to 98.7)
OG00266.7(9.4 to 99.2)
OG003
Month 24
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
study eyesOG0003
study eyesOG0011
study eyesOG0023
study eyesOG0033
study eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 97.5)
OG00233.3(0.8 to 90.6)
OG003
3
OG0043
OG0053
eyes
OG0006
OG0014
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.33± 1.748
OG0011.78± 1.282
OG0023.35± 0.911
OG0036.52± 3.398
OG00413.46± 6.316
OG0057.75± 7.742
Baseline: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.23± 1.358
OG0013.31± 2.563
OG0026.92± 2.221
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.52± 0.477
OG001-0.09± 0.928
OG0026.10± 0.844
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.42± 1.122
OG001-0.81± 1.768
OG002-0.98± 1.531
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.40± 0.407
OG0010.47± 1.282
OG0025.63± 2.394
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.06± 0.534
OG001-0.91± 0.575
OG002-1.15± 2.094
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.54± 0.485
OG001-0.06± 0.265
OG0025.10± 1.890
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.17± 0.344
OG001-0.34± 2.607
OG002-1.19± 1.535
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.21± 0.219
OG0010.09± 1.282
OG0024.65± 3.851
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.35± 0.509
OG0010.19± 2.210
OG0020.20± 2.751
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.19± 0.272
OG0010.13± 1.945
OG0024.10± 2.908
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.10± 0.355
OG001-1.09± 1.370
OG002-1.02± 0.581
OG003
Change From Baseline at Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.21± 0.473
OG001-1.13± 0.177
OG0022.69± 2.507
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.33± 0.577
OG001-1.09± 1.282
OG0020.02± 0.940
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0011
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.04± 0.253
OG001-1.88± NAStandard deviation (SD) cannot be estimated for 1 participant.
OG0022.75± 2.683
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0011
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.46± 0.469
OG001-1.63± NASD cannot be estimated for 1 participant.
OG002-0.33± 1.347
OG003
3
OG0043
OG0053
eyes
OG0006
OG0014
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG000-0.19± 0.690
OG0010.20± 0.281
OG0020.21± 0.435
OG0032.22± 1.536
OG0048.87± 10.784
OG0054.26± 6.732
Baseline: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.38± 0.540
OG0011.47± 1.061
OG0021.50± 1.419
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.12± 0.309
OG0010.24± 1.185
OG0022.42± 0.283
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.18± 0.481
OG001-0.76± 1.165
OG002-0.08± 0.938
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.14± 0.137
OG0010.74± 1.820
OG0022.44± 1.564
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.06± 0.292
OG001-0.29± 1.549
OG002-0.29± 1.351
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.04± 0.334
OG0010.19± 0.957
OG0022.28± 1.534
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.24± 0.331
OG001-0.32± 1.872
OG002-0.51± 0.773
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.18± 0.145
OG0010.31± 1.456
OG0022.02± 2.177
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.37± 0.467
OG001-0.12± 1.830
OG0021.66± 1.790
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.16± 0.165
OG0010.30± 1.612
OG0021.72± 1.892
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.30± 0.417
OG001-0.46± 1.633
OG002-0.24± 0.153
OG003
Change From Baseline at Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.23± 0.213
OG001-0.50± 0.458
OG0021.16± 1.144
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0012
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.33± 0.412
OG001-0.57± 1.435
OG0020.07± 0.509
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0011
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.40± 0.382
OG001-0.96± NASD cannot be estimated for 1 participant.
OG0021.17± 1.190
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0011
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0011
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.37± 0.427
OG001-1.44± NASD cannot be estimated for 1 participant.
OG0020.14± 0.221
OG003
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00027.67± 8.145
OG00149.67± 9.452
OG00264.33± 7.095
OG00363.67± 20.551
OG00470.67± 4.163
OG00567.33± 15.044
Baseline: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00060.67± 2.082
OG00157.33± 5.686
OG00266.33± 2.517
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0003.67± 3.055
OG0010.33± 2.517
OG002-1.00± 1.732
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0003.00± 3.000
OG0011.00± 4.359
OG0021.00± 1.000
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0006.33± 2.309
OG0010.00± 3.606
OG0020.67± 2.082
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0003.00± 1.000
OG0011.67± 1.528
OG002-1.67± 1.528
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0005.00± 1.000
OG001-3.67± 3.786
OG0020.33± 0.577
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-1.00± 7.211
OG001-0.67± 4.726
OG002-0.33± 3.215
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0001.33± 4.619
OG001-0.67± 0.577
OG0021.33± 4.509
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-5.00± 5.292
OG001-0.67± 5.033
OG0021.00± 1.000
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0004.67± 4.509
OG001-2.00± 3.464
OG0020.67± 5.132
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-1.67± 2.309
OG001-0.33± 3.215
OG002-0.33± 0.577
OG003
Change From Baseline at Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0003.00± 8.718
OG001-2.00± 3.606
OG002-3.33± 5.132
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-4.00± 6.245
OG0010.00± 5.000
OG002-0.33± 2.517
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-2.00± 15.588
OG001-2.00± 5.292
OG002-3.33± 3.215
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-3.67± 5.508
OG0010.67± 0.577
OG002-2.33± 1.528
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00241.00± 18.385
OG00334.33± 29.939
OG00458.00± 3.000
OG00541.67± 34.646
Baseline: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00237.50± 24.749
OG00337.67± 32.808
OG00461.00± 2.646
OG005
Change From Baseline at Month 1: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00210.00± 9.899
OG0030.33± 0.577
OG0043.00± 5.292
OG005
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00210.00± 18.385
OG003-0.33± 7.506
OG0043.00± 5.196
OG005
Change From Baseline at Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00214.00± 11.314
OG0037.33± 6.658
OG004-14.33± 38.214
OG005
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00210.00± 16.971
OG0031.00± 1.000
OG0043.00± 4.583
OG005
Change From Baseline at Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00211.50± 7.778
OG0038.33± 7.234
OG004-16.67± 35.810
OG005
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0028.00± 15.556
OG0031.67± 2.887
OG0045.33± 1.155
OG005
Change From Baseline at Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.50± 4.950
OG00310.00± 6.557
OG004-14.33± 37.820
OG005
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.50± 4.950
OG0032.00± 4.359
OG0042.00± 3.464
OG005
Change From Baseline at Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0023.50± 0.707
OG00316.00± 13.454
OG004-11.33± 40.612
OG005
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0027.00± 9.899
OG0036.67± 8.327
OG0049.00± 4.359
OG005
Change From Baseline at Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0026.50± 7.778
OG00310.67± 8.622
OG004-12.33± 40.079
OG005
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0029.00± 21.213
OG0032.33± 2.517
OG0045.67± 4.726
OG005
Change From Baseline at Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0023.00± 8.485
OG0039.33± 14.295
OG004-14.67± 38.371
OG005
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0025.50± 24.749
OG0030.67± 4.041
OG0043.33± 3.512
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00566.7(9.4 to 99.2)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00366.7(9.4 to 99.2)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00366.7(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG00333.3(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG00566.7(9.4 to 99.2)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.03(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG00233.3(0.8 to 90.6)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG0010.0(0.0 to 70.8)
OG00233.3(0.8 to 90.6)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG00133.3(0.8 to 90.6)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG00366.7(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG00366.7(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00466.7(9.4 to 99.2)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00366.7(9.4 to 99.2)
OG00466.7(9.4 to 99.2)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG004100.0(29.2 to 100.0)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00366.7(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00366.7(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0052
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0052
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.0 to 70.8)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0032
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG00333.3(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG00133.3(0.8 to 90.6)
OG0020.0(0.0 to 70.8)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG00133.3(0.8 to 90.6)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG00133.3(0.8 to 90.6)
OG0020.0(0.0 to 70.8)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG00233.3(0.8 to 90.6)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.0(0.0 to 70.8)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG00133.3(0.8 to 90.6)
OG00233.3(0.8 to 90.6)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 90.6)
OG00133.3(0.8 to 90.6)
OG0020.0(0.0 to 70.8)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 99.2)
OG00133.3(0.8 to 90.6)
OG00233.3(0.8 to 90.6)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG0010.0(0.0 to 70.8)
OG0020.0(0.0 to 70.8)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG00333.3(0.8 to 90.6)
OG0040.00(0.0 to 70.8)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG0020.0(0.0 to 84.2)
OG0030.0(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG0030.0(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG00366.7(9.4 to 99.2)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG00166.7(9.4 to 99.2)
OG002100.0(29.2 to 100.0)
OG003
Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG00166.7(9.4 to 99.2)
OG002100.0(29.2 to 100.0)
OG003
Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG00166.7(9.4 to 99.2)
OG002100.0(29.2 to 100.0)
OG003
Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG00266.7(9.4 to 99.2)
OG003
Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000100.0(29.2 to 100.0)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG00166.7(9.4 to 99.2)
OG00266.7(9.4 to 99.2)
OG003
Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00033.3(0.8 to 90.6)
OG00166.7(9.4 to 99.2)
OG002100.0(29.2 to 100.0)
OG003
Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG00166.7(9.4 to 99.2)
OG00266.7(9.4 to 99.2)
OG003
Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG00066.7(9.4 to 99.2)
OG001100.0(29.2 to 100.0)
OG002100.0(29.2 to 100.0)
OG003
3
OG0043
OG0053
eyes
OG0000
OG0010
OG0024
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG00566.7(9.4 to 99.2)
Month 1: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG00366.7(9.4 to 99.2)
OG004100.0(29.2 to 100.0)
OG005
Month 3: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 3: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
Month 9: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 9: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
Month 18: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 18: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG002100.0(15.8 to 100.0)
OG003100.0(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG005
Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0022
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0000
eyesOG0010
eyesOG0022
eyesOG0033
eyesOG004
Title
Measurements
OG00250.0(1.3 to 98.7)
OG003100.0(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.140± 0.1637
OG0012.750± 4.7631
OG0020.137± 0.1582
OG0030.193± 0.1686
OG0048.327± 13.8600
OG0053.107± 5.2001
Baseline: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG0000.130± 0.0985
OG0012.313± 3.7500
OG0020.093± 0.0814
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.077± 0.1159
OG001-0.493± 0.8545
OG002-0.103± 0.1050
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.060± 0.0265
OG001-0.383± 0.4508
OG002-0.020± 0.0693
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0042
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.100± 0.1249
OG001-0.560± 0.9699
OG002-0.110± 0.1153
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.093± 0.0404
OG001-0.407± 0.4895
OG002-0.043± 0.0379
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.120± 0.1375
OG001-0.527± 0.9122
OG002-0.113± 0.1206
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.093± 0.0404
OG001-0.410± 0.4951
OG002-0.060± 0.0529
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.127± 0.1419
OG001-0.540± 0.9353
OG002-0.117± 0.1258
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.097± 0.0451
OG001-0.437± 0.5326
OG002-0.063± 0.0569
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.130± 0.1473
OG001-0.560± 0.9699
OG002-0.117± 0.1258
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.097± 0.0451
OG001-0.447± 0.5353
OG002-0.033± 0.1266
OG003
Change From Baseline at Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.133± 0.1528
OG001-0.567± 0.9815
OG002-0.137± 0.1582
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG0000.1528± 0.0709
OG001-0.450± 0.5408
OG002-0.027± 0.1201
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.133± 0.1528
OG001-0.573± 0.9930
OG002-0.137± 0.1582
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-0.117± 0.0764
OG001-0.443± 0.5297
OG002-0.060± 0.0794
OG003
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG000162.67± 175.104
OG0011375.33± 2382.147
OG002248.00± 275.158
OG003462.33± 400.775
OG0042411.33± 3048.253
OG005745.67± 774.448
Baseline: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000355.67± 378
OG0011383.67± 396.581
OG002250.00± 33.139
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-56.33± 73.894
OG001-311.00± 538.668
OG002-174.00± 162.567
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-62.33± 40.216
OG001-321.67± 557.143
OG00247.33± 226.509
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-73.00± 70.193
OG001-318.00± 550.792
OG002-174.33± 163.022
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-149.00± 80.988
OG001-333.33± 577.350
OG002-60.67± 78.258
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-115.67± 105.624
OG001-318.67± 551.947
OG002-175.67± 164.852
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-158.67± 65.033
OG001-347.00± 601.022
OG002-76.33± 79.135
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-127.00± 121.025
OG001-321.33± 556.566
OG002-178.33± 168.548
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0052
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-175.00± 39.585
OG001-348.00± 602.754
OG002-77.33± 79.053
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-130.00± 125.300
OG001-238.33± 412.805
OG002-217.00± 225.980
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-181.67± 30.665
OG001-349.33± 605.063
OG002-35.67± 255.895
OG003
Change From Baseline at Month 18: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-131.00± 126.740
OG001-239.33± 414.537
OG002-248.00± 275.158
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-316.67± 213.601
OG001-354.67± 614.301
OG002-168.67± 161.122
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-131.33± 127.222
OG001-242.33± 419.734
OG002-248.00± 275.158
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0032
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0032
eyesOG004
Title
Measurements
OG000-329.33± 235.434
OG001-358.00± 620.074
OG002-145.67± 162.543
OG003
0
OG0040
OG0050
eyes
OG0002
OG0010
OG0022
OG0030
OG0040
OG0050
0
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG0040
eyesOG0050
Title
Measurements
OG00027.050± NASD cannot be estimated for 1 participant.
Baseline: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG00022.910± NASD cannot be estimated for 1 participant.
OG00250.640± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 1: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-1.820± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-2.420± NASD cannot be estimated for 1 participant.
OG002-8.620± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 3: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-2.940± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-2.650± NASD cannot be estimated for 1 participant.
OG002-5.150± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.460± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.050± NASD cannot be estimated for 1 participant.
OG002-6.530± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 9: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.470± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.100± NASD cannot be estimated for 1 participant.
OG002-9.130± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.640± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.760± NASD cannot be estimated for 1 participant.
OG002-9.220± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 18: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.670± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0021
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.830± NASD cannot be estimated for 1 participant.
OG002-11.700± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-3.740± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
eyesOG0001
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG000-4.120± NASD cannot be estimated for 1 participant.
1
OG0041
OG0051
eyes
OG0004
OG0012
OG0022
OG0032
OG0042
OG0052
1
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG0041
eyesOG0050
Title
Measurements
OG0002394.50± 665.387
OG001-39.00± NASD cannot be estimated for 1 participant.
OG0023018.00± NASD cannot be estimated for 1 participant.
OG003361.00± NASD cannot be estimated for 1 participant.
OG0042853.00± NASD cannot be estimated for 1 participant.
Baseline: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0051
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG0002609.00± 386.080
OG001-24.00± NASD cannot be estimated for 1 participant.
OG0023052.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 1: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-33.00± 5.657
OG001-14.00± NASD cannot be estimated for 1 participant.
OG002-52.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0051
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-255.50± 297.692
OG001-19.00± NASD cannot be estimated for 1 participant.
OG002-281.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-87.00± 24.042
OG001-16.00± NASD cannot be estimated for 1 participant.
OG002-138.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0051
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-276.50± 324.562
OG001-30.00± NASD cannot be estimated for 1 participant.
OG002-375.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-128.50± 54.447
OG001-24.00± NASD cannot be estimated for 1 participant.
OG002-179.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-297.00± 349.311
OG001-41.00± NASD cannot be estimated for 1 participant.
OG002-462.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 9: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-140.00± 41.012
OG001-35.00± NASD cannot be estimated for 1 participant.
OG002-281.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-310.50± 333.047
OG001-58.00± NASD cannot be estimated for 1 participant.
OG002-413.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0002
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0010
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-1489.50± 1829.285
OG002-282.00± NASD cannot be estimated for 1 participant.
OG003-101.00± NASD cannot be estimated for 1 participant.
OG004
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0010
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-353.50± 318.905
OG002-422.00± NASD cannot be estimated for 1 participant.
OG003-39.00± NASD cannot be estimated for 1 participant.
OG004
Change From Baseline at Month 18: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-1493.00± 1829.992
OG001-55.00± NASD cannot be estimated for 1 participant.
OG002-310.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 18: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-358.00± 318.198
OG001-86.00± NASD cannot be estimated for 1 participant.
OG002-425.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-1501.00± 1820.093
OG001-69.00± NASD cannot be estimated for 1 participant.
OG002-226.00± NASD cannot be estimated for 1 participant.
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0031
ParticipantsOG0041
ParticipantsOG0050
eyesOG0002
eyesOG0011
eyesOG0021
eyesOG0031
eyesOG004
Title
Measurements
OG000-391.00± 301.227
OG001-91.00± NASD cannot be estimated for 1 participant.
OG002-2646.00± NASD cannot be estimated for 1 participant.
OG003
0
OG0041
OG0051
eyes
OG0000
OG0010
OG0020
OG0030
OG0042
OG0052
0
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG0041
eyesOG0051
Title
Measurements
OG0042.73± NASD cannot be estimated for 1 participant.
OG0055.07± NASD cannot be estimated for 1 participant.
Baseline: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG0055.17± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-2.14± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-1.10± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG0040.33± NASD cannot be estimated for 1 participant.
OG005-2.80± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-1.02± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG004-1.89± NASD cannot be estimated for 1 participant.
OG005-3.08± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-2.11± NASD cannot be estimated for 1 participant.
0
OG0041
OG0051
eyes
OG0000
OG0010
OG0020
OG0030
OG0042
OG0052
0
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG0041
eyesOG0051
Title
Measurements
OG00415.77± NASD cannot be estimated for 1 participant.
OG00518.31± NASD cannot be estimated for 1 participant.
Baseline: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG00523.41± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-0.86± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-4.91± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG0041.29± NASD cannot be estimated for 1 participant.
OG005-2.98± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-3.70± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0041
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG004-6.28± NASD cannot be estimated for 1 participant.
OG005-5.36± NASD cannot be estimated for 1 participant.
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0051
eyesOG0000
eyesOG0010
eyesOG0020
eyesOG0030
eyesOG004
Title
Measurements
OG005-7.87± NASD cannot be estimated for 1 participant.
3
OG0043
OG0053
eyes
OG0006
OG0016
OG0026
OG0036
OG0046
OG0056
3
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG0043
eyesOG0053
Title
Measurements
OG0000.300± 0.1732
OG0010.533± 0.2309
OG0020.900± 0.1732
OG0030.883± 0.3884
OG0041.267± 0.0289
OG0051.067± 0.6110
Baseline: Non-Study
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.433± 0.2082
OG0010.583± 0.2255
OG0021.050± 0.2598
OG003
Change From Baseline at Month 3: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.167± 0.1528
OG0010.183± 0.2566
OG0020.150± 0.0866
OG003
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.000± 0.0000
OG0010.017± 0.4010
OG0020.050± 0.0500
OG003
Change From Baseline at Month 6: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.133± 0.2082
OG0010.067± 0.2363
OG0020.100± 0.1323
OG003
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.000± 0.1732
OG0010.033± 0.2255
OG0020.083± 0.0764
OG003
Change From Baseline at Month 12: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.100± 0.2828
OG0010.133± 0.3512
OG002-0.017± 0.1041
OG003
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.100± 0.2828
OG0010.067± 0.3512
OG0020.000± 0.0000
OG003
Change From Baseline at Month 24: Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG0000.000± 0.2291
OG0010.017± 0.5965
OG002-0.100± 0.0000
OG003
Change From Baseline at Month 24: Non-Study Eye
ParticipantsOG0003
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0033
ParticipantsOG0043
ParticipantsOG0053
eyesOG0003
eyesOG0013
eyesOG0023
eyesOG0033
eyesOG004
Title
Measurements
OG000-0.183± 0.1258
OG0010.117± 0.3884
OG002-0.100± 0.1732
OG003
9
OG00110
OG00210
9
study eyesOG00110
study eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00130.0(11.6 to 55.2)
OG00240.0(18.8 to 64.6)
Month 2
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
study eyesOG0009
study eyesOG00110
study eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00130.0(11.6 to 55.2)
OG00250.0(26.7 to 73.3)
Month 3
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
study eyesOG0008
study eyesOG00110
study eyesOG00210
Title
Measurements
OG00012.5(1.3 to 40.6)
OG00130.0(11.6 to 55.2)
OG00260.0(35.4 to 81.2)
Month 6
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
study eyesOG0009
study eyesOG0019
study eyesOG0028
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00133.3(12.9 to 59.9)
OG00262.5(34.5 to 85.3)
Month 9
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG0027
study eyesOG0009
study eyesOG0017
study eyesOG0027
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00128.6(7.9 to 59.6)
OG00242.9(17.0 to 72.1)
9
OG00110
OG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00180.0(55.0 to 94.5)
OG00280.0(55.0 to 94.5)
Month 3
Title
Measurements
OG00025.0(6.9 to 53.8)
OG00180.0(55.0 to 94.5)
OG00270.0(44.8 to 88.4)
Month 6
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00177.8(51.0 to 93.9)
OG002100.0(75.0 to 100.0)
Month 9
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00185.7(54.7 to 98.5)
OG00271.4(40.4 to 92.1)
Month 12
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00162.5(34.5 to 85.3)
OG00262.5(34.5 to 85.3)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0006.78± 3.488
OG0017.39± 5.207
OG0027.38± 3.095
Baseline: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0009.56± 3.321
OG0019.09± 5.003
OG0028.98± 3.583
Change From Baseline at Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0001.53± 3.086
OG0012.70± 3.731
OG0020.10± 5.723
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.26± 1.692
OG001-0.76± 1.793
OG002-0.08± 0.834
Change From Baseline at Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0001.62± 2.846
OG0012.73± 4.360
OG0021.55± 5.886
Change From Baseline at Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.34± 2.027
OG001-0.44± 1.723
OG0020.26± 1.118
Change From Baseline at Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0001.17± 2.760
OG0012.77± 4.598
OG0021.00± 6.862
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG000-1.24± 1.253
OG0010.07± 1.393
OG002-0.24± 0.500
Change From Baseline at Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.72± 3.208
OG0013.38± 4.770
OG0023.74± 3.931
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-0.69± 2.199
OG001-0.35± 1.125
OG002-0.66± 0.702
Change From Baseline at Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG0027
eyesOG0009
eyesOG0017
eyesOG0027
Title
Measurements
OG0000.65± 3.272
OG0012.52± 4.619
OG0022.54± 6.317
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000-1.01± 1.943
OG0010.30± 1.654
OG002-0.54± 0.636
Change From Baseline at Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
eyesOG0009
eyesOG0018
eyesOG0028
Title
Measurements
OG000-0.11± 4.446
OG0012.79± 4.663
OG0021.16± 5.660
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-2.23± 4.018
OG001-0.44± 1.078
OG002-1.04± 1.292
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0002.15± 2.182
OG0012.46± 1.911
OG0023.84± 2.138
Baseline: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0003.32± 2.539
OG0013.34± 2.092
OG0024.47± 2.331
Change From Baseline at Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.91± 1.389
OG0011.60± 2.225
OG002-0.07± 3.898
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.12± 1.214
OG001-0.46± 1.044
OG002-0.03± 0.850
Change From Baseline at Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.90± 0.972
OG0012.34± 2.353
OG0021.18± 3.367
Change From Baseline at Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.30± 1.111
OG001-0.23± 0.859
OG0020.13± 0.668
Change From Baseline at Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.46± 1.064
OG0012.64± 2.962
OG0020.24± 3.962
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.16± 0.743
OG001-0.03± 0.516
OG002-0.11± 0.619
Change From Baseline at Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.32± 1.301
OG0013.15± 3.283
OG0022.05± 3.007
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-0.13± 1.283
OG001-0.27± 0.527
OG002-0.50± 0.632
Change From Baseline at Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG0027
eyesOG0009
eyesOG0017
eyesOG0027
Title
Measurements
OG0000.40± 1.456
OG0012.80± 3.116
OG0021.71± 3.605
Change From Baseline at Month 9: Non- Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000-0.41± 1.150
OG001-0.05± 0.790
OG0020.09± 0.544
Change From Baseline at Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
eyesOG0009
eyesOG0018
eyesOG0028
Title
Measurements
OG0000.11± 1.592
OG0012.79± 3.045
OG0020.89± 3.132
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-0.84± 1.749
OG001-0.28± 0.476
OG002-0.35± 1.004
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00068.78± 5.954
OG00165.90± 10.104
OG00268.20± 8.991
Baseline: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00072.89± 6.846
OG00168.50± 9.675
OG00268.80± 6.989
Change From Baseline at Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.44± 2.833
OG0011.60± 6.450
OG0020.60± 7.545
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.89± 2.028
OG0010.00± 4.110
OG0023.80± 3.360
Change From Baseline at Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.22± 2.108
OG001-1.00± 12.392
OG0020.00± 8.957
Change From Baseline at Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.11± 1.269
OG0010.60± 2.836
OG0023.10± 2.644
Change From Baseline at Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0001.38± 2.615
OG0010.10± 6.540
OG002-0.30± 11.036
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.13± 2.642
OG0011.10± 2.470
OG0023.20± 2.860
Change From Baseline at Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0001.00± 2.000
OG0012.44± 5.003
OG002-0.38± 5.630
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-1.56± 2.833
OG0010.67± 1.581
OG0021.00± 4.629
Change From Baseline at Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.44± 1.944
OG001-2.50± 14.263
OG002-0.57± 1.397
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000-1.78± 2.949
OG0011.00± 2.000
OG0021.71± 3.147
Change From Baseline at Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.22± 2.949
OG001-4.00± 17.436
OG002-0.75± 3.370
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0027
eyesOG0009
eyesOG0019
eyesOG0027
Title
Measurements
OG000-4.11± 3.983
OG0010.89± 3.100
OG0022.14± 3.976
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00050.22± 13.349
OG00139.30± 22.246
OG00247.90± 14.970
Baseline: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00054.78± 11.872
OG00149.50± 19.127
OG00251.60± 9.524
Change From Baseline at Month 1: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.56± 7.618
OG00111.30± 16.918
OG002-1.30± 18.397
Change From Baseline at Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.22± 5.215
OG001-3.00± 9.165
OG0023.50± 4.882
Change From Baseline at Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0003.63± 7.230
OG0018.10± 16.251
OG002-3.50± 22.609
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG000-0.63± 8.158
OG0010.50± 3.749
OG0021.20± 3.553
Change From Baseline at Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0001.22± 7.032
OG0018.00± 18.581
OG0023.25± 14.636
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.11± 6.274
OG001-3.56± 8.472
OG0022.13± 2.850
Change From Baseline at Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000-1.78± 7.225
OG0018.38± 16.088
OG0026.00± 12.356
Change From Baseline at Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000-3.11± 7.491
OG001-1.13± 6.749
OG0024.00± 4.082
Change From Baseline at Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-2.22± 7.412
OG0015.11± 14.426
OG002-0.63± 11.575
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000-4.44± 7.002
OG001-3.56± 11.652
OG002-1.50± 4.309
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG00210.0(1.0 to 33.7)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 20.6)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG00210.0(1.0 to 33.7)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 22.6)
OG00210.0(1.0 to 33.7)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 25.0)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 25.0)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 25.0)
OG0020.0(0.0 to 28.0)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 25.0)
OG0020.0(0.0 to 28.0)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 25.0)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0027
eyesOG0009
eyesOG0019
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 28.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00140.0(18.8 to 64.6)
OG00220.0(5.5 to 45.0)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00140.0(18.8 to 64.6)
OG00230.0(11.6 to 55.2)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00133.3(12.9 to 59.9)
OG00212.5(1.3 to 40.6)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 0.0)
OG0020.0(0.0 to 25.0)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00125.0(6.9 to 53.8)
OG00228.6(7.9 to 59.6)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 25.0)
OG0020.0(0.0 to 28.0)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00133.3(12.9 to 59.9)
OG00212.5(1.3 to 40.6)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 25.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG00220.0(5.5 to 45.0)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 3: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG00212.5(1.3 to 40.6)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 25.0)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 28.0)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 25.0)
OG0020.0(0.0 to 28.0)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG0020.0(0.0 to 25.0)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0027
eyesOG0009
eyesOG0019
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 28.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00140.0(18.8 to 64.6)
OG00230.0(11.6 to 55.2)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00025.0(6.9 to 53.8)
OG00140.0(18.8 to 64.6)
OG00230.0(11.6 to 55.2)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00012.5(1.3 to 40.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00144.4(21.0 to 69.9)
OG00214.7(14.7 to 65.5)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00111.1(1.2 to 36.8)
OG0020.0(0.0 to 25.0)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00137.5(14.7 to 65.5)
OG00228.6(7.9 to 59.6)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00112.5(1.3 to 40.6)
OG00214.3(1.5 to 45.3)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00133.3(12.9 to 59.9)
OG00212.5(1.3 to 40.6)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG0020.0(0.0 to 25.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00160.0(35.4 to 81.2)
OG00220.0(5.5 to 45.0)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG00240.0(18.8 to 64.6)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00160.0(35.4 to 81.2)
OG00230.0(11.6 to 55.2)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG00230.0(11.6 to 55.2)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00012.5(1.3 to 40.6)
OG00120.0(5.5 to 45.0)
OG00230.0(11.6 to 55.2)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 20.6)
OG00220.0(5.5 to 45.0)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00144.4(21.0 to 69.9)
OG00212.5(1.3 to 40.6)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG00225.0(6.9 to 53.8)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00137.5(14.7 to 65.5)
OG0020.0(0.0 to 28.0)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 25.0)
OG00242.9(17.0 to 72.1)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00122.2(6.1 to 49.0)
OG0020.0(0.0 to 25.0)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0027
eyesOG0009
eyesOG0019
eyesOG0027
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG00228.6(7.9 to 59.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00160.0(35.4 to 81.2)
OG00240.0(18.8 to 64.6)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00130.0(11.6 to 55.2)
OG00230.0(11.6 to 55.2)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00037.5(14.7 to 65.5)
OG00150.0(26.7 to 73.3)
OG00230.0(11.6 to 55.2)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00025.0(25.0 to 53.8)
OG00120.0(5.5 to 45.0)
OG00210.0(1.0 to 33.7)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00044.4(21.0 to 69.9)
OG00166.7(40.1 to 87.1)
OG00250.0(24.0 to 76.0)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00111.1(1.2 to 36.8)
OG00225.0(6.9 to 53.8)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00162.5(34.5 to 85.3)
OG00257.1(27.9 to 83.0)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00112.5(1.3 to 40.6)
OG00242.9(17.0 to 72.1)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00144.4(21.0 to 69.9)
OG00212.5(1.3 to 40.6)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00122.2(6.1 to 49.0)
OG0020.0(0.0 to 25.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 18.9)
OG0028.3(0.9 to 28.7)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
Month 2: Non- Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 18.9)
OG0028.3(0.9 to 28.7)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG00211.1(1.2 to 36.8)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0029
eyesOG0009
eyesOG00110
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 222.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 22.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 18.9)
OG00233.3(15.4 to 55.9)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00118.2(4.9 to 41.5)
OG0020.0(0.0 to 17.5)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0019.1(1.0 to 31.0)
OG00233.3(15.4 to 55.9)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG00220.0(5.5 to 45.0)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG00211.1(1.2 to 36.8)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG00220.0(5.5 to 45.0)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0019.1(1.0 to 31.0)
OG0028.3(0.9 to 28.7)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG00210.0(1.0 to 33.7)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0019.1(1.0 to 31.0)
OG0028.3(0.9 to 28.7)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 20.6)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00111.1(1.2 to 36.8)
OG00211.1(1.2 to 36.8)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG00210.0(1.0 to 33.7)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0029
eyesOG0009
eyesOG00110
eyesOG0029
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0010.0(0.0 to 20.6)
OG0020.0(0.0 to 22.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0010.0(0.0 to 18.9)
OG00233.3(15.4 to 55.9)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00118.2(4.9 to 41.5)
OG0020.0(0.0 to 17.5)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG00118.2(4.9 to 41.5)
OG00233.3(15.4 to 55.9)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00012.5(1.3 to 40.6)
OG0010.0(0.0 to 18.9)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG00220.0(5.5 to 45.0)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG0020.0(0.0 to 20.6)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00011.1(1.2 to 22.6)
OG00111.1(1.2 to 36.8)
OG00211.1(1.2 to 36.8)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0010.0(0.0 to 0.0)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG00230.0(11.6 to 55.2)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0019.1(1.0 to 31.0)
OG00233.3(15.4 to 55.9)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00011.1(1.2 to 36.8)
OG0019.1(1.0 to 31.0)
OG0020.0(0.0 to 17.5)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00120.0(5.5 to 45.0)
OG00240.0(18.8 to 64.6)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0029
eyesOG0009
eyesOG00110
eyesOG0029
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 20.6)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG00118.2(4.9 to 41.5)
OG00233.3(15.4 to 55.9)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 25.0)
OG00118.2(4.9 to 41.5)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.0(0.0 to 22.6)
OG00110.0(1.0 to 33.7)
OG00230.0(11.6 to 55.2)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG0010.0(0.0 to 20.6)
OG00210.0(1.0 to 33.7)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00022.2(6.1 to 49.0)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 22.6)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00022.2(6.1 to 49.0)
OG0010.0(0.0 to 22.6)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00011.1(1.2 to 36.8)
OG00120.0(5.5 to 22.6)
OG00220.0(5.5 to 45.0)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0029
eyesOG0009
eyesOG00110
eyesOG0029
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00110.0(1.0 to 33.7)
OG0020.0(0.0 to 22.6)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00118.2(4.9 to 41.5)
OG00241.7(21.9 to 63.8)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00136.4(16.9 to 59.9)
OG0020.0(0.0 to 17.5)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00012.5(1.3 to 40.6)
OG00118.2(4.9 to 41.5)
OG00241.7(21.9 to 63.8)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00037.5(14.7 to 65.5)
OG0019.1(1.0 to 31.0)
OG0020.0(0.0 to 17.5)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00022.2(6.1 to 49.0)
OG00120.0(5.5 to 45.0)
OG00230.0(11.6 to 55.2)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00150.0(26.7 to 73.3)
OG0020.0(0.0 to 20.6)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00033.3(12.9 to 59.9)
OG00122.2(6.1 to 49.0)
OG00233.3(12.9 to 59.9)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0029
eyesOG0009
eyesOG0019
eyesOG0029
Title
Measurements
OG00055.6(30.1 to 79.0)
OG00133.3(12.9 to 59.9)
OG0020.0(0.0 to 22.6)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00055.6(30.1 to 79.0)
OG00130.0(11.6 to 55.2)
OG00240.0(18.8 to 64.6)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00044.4(21.0 to 69.9)
OG00140.0(18.8 to 64.6)
OG00230.0(11.6 to 55.2)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00088.9(63.2 to 98.8)
OG00190.0(66.3 to 99.0)
OG00270.0(44.8 to 88.4)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00088.9(63.2 to 98.8)
OG00190.0(66.3 to 99.0)
OG002100.0(79.4 to 100.0)
Month 2: Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000100.0(77.4 to 100.0)
OG00180.0(55.0 to 94.5)
OG00260.0(35.4 to 81.2)
Month 2: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG000100.0(77.4 to 100.0)
OG00190.0(66.3 to 99.0)
OG002100.0(79.4 to 100.0)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG000100.0(75.0 to 100.0)
OG00180.0(55.0 to 94.5)
OG00270.0(44.8 to 88.4)
Month 3: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG000100.0(75.0 to 100.0)
OG00190.0(66.3 to 99.0)
OG002100.0(79.4 to 100.0)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG000100.0(77.4 to 100.0)
OG00188.9(63.2 to 98.8)
OG00275.0(46.2 to 93.1)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00077.8(51.0 to 93.9)
OG001100.0(77.4 to 100.0)
OG00287.5(59.4 to 98.7)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG000100.0(77.4 to 100.0)
OG00175.0(46.2 to 93.1)
OG002100.0(72.0 to 100.0)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00077.8(51.0 to 93.9)
OG001100.0(75.0 to 100.0)
OG002100.0(72.0 to 100.0)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00088.9(63.2 to 98.8)
OG00177.8(51.0 to 93.9)
OG00287.5(59.4 to 98.7)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0027
eyesOG0009
eyesOG0019
eyesOG0027
Title
Measurements
OG00066.7(40.1 to 87.1)
OG00188.9(63.2 to 98.8)
OG002100.0(72.0 to 100.0)
18
OG00120
OG00220
9
eyesOG00110
eyesOG00210
Title
Measurements
OG00066.7(40.1 to 87.1)
OG00180.0(55.0 to 94.5)
OG00270.0(44.8 to 88.4)
Month 1: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00066.7(40.1 to 87.1)
OG00160.0(35.4 to 81.2)
OG002100.0(79.4 to 100.0)
Month 3: Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG00087.5(59.4 to 98.7)
OG00180.0(55.0 to 94.5)
OG00260.0(35.4 to 81.2)
Month 3: Non-Study Eye
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00210
eyesOG0009
eyesOG00110
eyesOG00210
Title
Measurements
OG00062.5(34.5 to 85.3)
OG001100.0(79.4 to 100.0)
OG002100.0(79.4 to 100.0)
Month 6: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00077.8(51.0 to 93.9)
OG00177.8(51.0 to 93.9)
OG00275.0(46.2 to 93.1)
Month 6: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00066.7(40.1 to 87.1)
OG00144.4(21.0 to 69.9)
OG002100.0(75.0 to 100.0)
Month 9: Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00066.7(40.1 to 87.1)
OG00175.0(46.2 to 93.1)
OG00271.4(40.4 to 92.1)
Month 9: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0027
eyesOG0009
eyesOG0018
eyesOG0027
Title
Measurements
OG00044.4(21.0 to 69.9)
OG00162.5(34.5 to 85.3)
OG002100.0(72.0 to 100.0)
Month 12: Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00044.4(21.0 to 69.9)
OG00166.7(40.1 to 87.1)
OG00275.0(46.2 to 93.1)
Month 12: Non-Study Eye
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
eyesOG0009
eyesOG0019
eyesOG0028
Title
Measurements
OG00055.6(30.1 to 79.0)
OG00155.6(30.1 to 79.0)
OG00262.5(34.5 to 85.3)
16
OG00120
OG00220
8
eyesOG00110
eyesOG00210
Title
Measurements
OG0003.61± 3.436
OG0013.58± 2.549
OG0025.70± 3.161
Baseline: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0003.05± 3.223
OG0013.71± 2.668
OG0026.23± 2.956
Change From Baseline at Month 3: Study Eye
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
eyesOG0007
eyesOG00110
eyesOG0028
Title
Measurements
OG0000.80± 1.236
OG0010.63± 1.162
OG002-0.01± 5.288
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG00210
eyesOG0007
eyesOG00110
eyesOG00210
Title
Measurements
OG0000.52± 1.315
OG0010.45± 0.759
OG002-0.02± 1.110
Change From Baseline at Month 6: Study Eye
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG0027
eyesOG0008
eyesOG0018
eyesOG0027
Title
Measurements
OG0000.13± 0.499
OG0010.57± 1.354
OG002-1.22± 1.566
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
eyesOG0007
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.20± 0.516
OG0010.30± 0.665
OG0020.19± 0.576
Change From Baseline at Month 12: Study Eye
ParticipantsOG0007
ParticipantsOG0018
ParticipantsOG0028
eyesOG0007
eyesOG0018
eyesOG0028
Title
Measurements
OG000-0.36± 0.615
OG0010.26± 1.164
OG002-1.91± 1.498
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0007
ParticipantsOG0018
ParticipantsOG0028
eyesOG0007
eyesOG0018
eyesOG0028
Title
Measurements
OG0000.29± 0.487
OG001-0.10± 0.781
OG002-0.56± 0.337
16
OG00120
OG00220
8
eyesOG00110
eyesOG00210
Title
Measurements
OG0007.26± 8.624
OG00117.51± 17.302
OG00219.48± 16.248
Baseline: Non-Study Eye
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00210
eyesOG0008
eyesOG00110
eyesOG00210
Title
Measurements
OG0007.05± 8.821
OG00116.33± 16.803
OG00221.08± 17.560
Change From Baseline at Month 3: Study Eye
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
eyesOG0007
eyesOG00110
eyesOG0028
Title
Measurements
OG0001.84± 3.168
OG0011.26± 3.327
OG002-0.10± 4.059
Change From Baseline at Month 3: Non-Study Eye
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG00210
eyesOG0007
eyesOG00110
eyesOG00210
Title
Measurements
OG0001.36± 2.460
OG0012.01± 2.832
OG0020.55± 3.097
Change From Baseline at Month 6: Study Eye
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG0027
eyesOG0008
eyesOG0018
eyesOG0027
Title
Measurements
OG000-0.35± 1.461
OG0010.98± 2.197
OG0021.52± 3.897
Change From Baseline at Month 6: Non-Study Eye
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
eyesOG0007
eyesOG0019
eyesOG0028
Title
Measurements
OG0000.46± 1.124
OG0010.99± 2.324
OG0021.38± 2.526
Change From Baseline at Month 12: Study Eye
ParticipantsOG0007
ParticipantsOG0018
ParticipantsOG0028
eyesOG0007
eyesOG0018
eyesOG0028
Title
Measurements
OG000-1.18± 1.302
OG0010.81± 3.709
OG002-0.95± 3.992
Change From Baseline at Month 12: Non-Study Eye
ParticipantsOG0007
ParticipantsOG0018
ParticipantsOG0028
eyesOG0007
eyesOG0018
eyesOG0028
Title
Measurements
OG0000.66± 1.193
OG0010.28± 2.736
OG002-0.91± 2.001
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
2
study eyesOG0053
33.3
(0.8 to 90.6)
OG00450.0(1.3 to 98.7)
OG00533.3(0.8 to 90.6)
3
study eyesOG0052
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 84.2)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00566.7(9.4 to 99.2)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG00466.7(9.4 to 99.2)
OG005100.0(29.2 to 100.0)
3
study eyesOG0053
33.3
(0.8 to 90.6)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
2
study eyesOG0053
66.7
(9.4 to 99.2)
OG00450.0(1.3 to 98.7)
OG00566.7(9.4 to 99.2)
3
study eyesOG0052
33.3
(0.8 to 90.6)
OG00466.7(9.4 to 99.2)
OG00550.0(1.3 to 98.7)
3
study eyesOG0053
66.7
(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 99.2)
3
eyesOG0053
8.21
± 5.570
OG00413.71± 8.447
OG0057.54± 7.542
3
eyesOG0053
1.19
± 6.094
OG004-0.63± 4.154
OG005-1.90± 7.686
3
eyesOG0053
-0.19
± 0.272
OG0041.40± 2.690
OG0050.19± 2.063
3
eyesOG0053
1.73
± 8.714
OG004-3.58± 7.476
OG005-3.35± 2.894
3
eyesOG0053
0.33
± 1.134
OG0042.06± 1.137
OG005-0.42± 0.289
3
eyesOG0053
3.25
± 8.199
OG004-2.38± 5.177
OG0050.85± 5.105
3
eyesOG0053
2.10
± 3.437
OG0042.19± 0.933
OG005-0.65± 1.156
3
eyesOG0053
3.69
± 6.308
OG004-2.50± 5.314
OG0050.77± 7.096
3
eyesOG0053
-0.06
± 1.789
OG0042.52± 1.714
OG0050.40± 2.032
2
eyesOG0053
3.98
± 5.090
OG0042.25± 2.121
OG0050.56± 5.590
2
eyesOG0053
0.42
± 1.951
OG0042.31± 2.990
OG005-0.29± 1.835
3
eyesOG0052
2.92
± 5.550
OG004-2.79± 6.733
OG005-1.09± 5.436
3
eyesOG0052
-0.67
± 0.806
OG0041.92± 3.085
OG005-0.59± 2.607
3
eyesOG0053
1.48
± 5.236
OG004-4.90± 5.250
OG005-1.88± 5.862
3
eyesOG0053
-0.56
± 1.207
OG0040.71± 3.263
OG005-2.19± 2.189
3
eyesOG0053
2.30
± 1.559
OG0049.11± 12.466
OG0055.35± 8.579
3
eyesOG0053
0.08
± 2.436
OG0040.56± 3.243
OG005-1.69± 4.341
3
eyesOG0053
-0.11
± 0.111
OG0041.24± 1.639
OG005-0.66± 1.474
3
eyesOG0053
0.58
± 5.061
OG004-1.87± 4.073
OG005-0.60± 1.383
3
eyesOG0053
0.68
± 1.223
OG0041.38± 1.005
OG005-0.65± 0.407
3
eyesOG0053
0.90
± 5.011
OG004-0.60± 1.596
OG0050.51± 2.154
3
eyesOG0053
3.86
± 5.648
OG0041.76± 0.470
OG005-0.84± 1.101
3
eyesOG0053
0.90
± 4.233
OG004-0.87± 2.229
OG005-0.13± 4.044
3
eyesOG0053
0.77
± 1.405
OG0042.05± 0.816
OG005-0.41± 1.157
2
eyesOG0053
1.28
± 3.541
OG004-0.22± 2.600
OG005-0.41± 4.208
2
eyesOG0053
0.76
± 1.345
OG0041.72± 1.144
OG005-0.82± 1.248
3
eyesOG0052
1.37
± 4.233
OG004-0.72± 1.253
OG005-1.32± 4.721
3
eyesOG0052
0.18
± 0.191
OG0041.24± 1.265
OG005-1.19± 2.267
3
eyesOG0053
0.98
± 3.510
OG004-2.37± 1.225
OG005-2.26± 6.009
3
eyesOG0053
0.24
± 0.153
OG0040.75± 1.427
OG005-1.73± 2.481
3
eyesOG0053
62.67
± 22.279
OG00473.33± 4.163
OG00575.00± 4.583
3
eyesOG0053
-1.33
± 6.506
OG004-0.67± 4.041
OG005-0.67± 10.693
3
eyesOG0053
0.33
± 0.577
OG0042.00± 4.583
OG005-2.67± 1.155
3
eyesOG0053
1.67
± 4.726
OG0040.33± 6.028
OG0050.67± 6.506
3
eyesOG0053
2.33
± 2.309
OG0044.67± 4.509
OG005-0.33± 0.577
3
eyesOG0053
3.67
± 5.686
OG004-3.67± 8.737
OG005-0.67± 5.033
3
eyesOG0053
3.67
± 3.055
OG0044.00± 4.359
OG005-0.67± 1.528
3
eyesOG0053
4.00
± 5.292
OG004-3.67± 16.073
OG005-2.33± 9.074
3
eyesOG0053
3.00
± 3.606
OG0045.67± 8.622
OG0052.00± 4.359
3
eyesOG0053
4.33
± 4.933
OG004-15.00± 40.286
OG005-2.33± 8.327
3
eyesOG0053
2.00
± 4.359
OG0046.67± 6.429
OG0051.00± 2.000
3
eyesOG0053
3.33
± 3.786
OG004-9.33± 28.919
OG005-5.00± 8.544
3
eyesOG0053
1.33
± 2.517
OG0045.00± 7.810
OG005-0.33± 5.508
3
eyesOG0053
5.00
± 7.000
OG004-13.33± 32.747
OG005-5.67± 6.110
3
eyesOG0053
2.33
± 4.509
OG0042.00± 7.810
OG005-2.00± 3.000
3
eyesOG0053
57.33
± 14.844
3
eyesOG0053
4.67
± 26.502
3
eyesOG0053
-4.33
± 7.572
3
eyesOG0053
-7.67
± 10.263
3
eyesOG0053
2.00
± 3.464
3
eyesOG0053
7.33
± 9.713
3
eyesOG0053
0.67
± 3.215
3
eyesOG0053
4.33
± 8.083
3
eyesOG0053
3.33
± 2.309
3
eyesOG0053
8.33
± 11.590
3
eyesOG0053
4.00
± 6.083
3
eyesOG0053
8.33
± 5.508
3
eyesOG0053
-4.33
± 7.234
3
eyesOG0053
-1.67
± 6.506
3
eyesOG0053
-12.67
± 11.547
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00466.7(9.4 to 99.2)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
66.7
(9.4 to 99.2)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00466.7(9.4 to 99.2)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG0050.0(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG00433.3(0.8 to 90.6)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
OG0040.0(0.0 to 70.8)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005100.0(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005100.0(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00433.3(0.8 to 90.6)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005100.0(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005100.0(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG005100.0(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG00466.7(9.4 to 99.2)
OG00533.3(0.8 to 90.6)
3
eyesOG0053
100.0
(29.2 to 100.0)
OG004100.0(29.2 to 100.0)
OG00566.7(9.4 to 99.2)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
100.0
(29.2 to 100.0)
3
eyesOG0053
33.3
(0.8 to 90.6)
3
eyesOG0053
66.7
(9.4 to 99.2)
3
eyesOG0053
0.0
(0.0 to 70.8)
3
eyesOG0053
0.465
± 0.1061
OG00414.307± 24.1914
OG0055.257± 8.8720
3
eyesOG0053
-0.050
± 0.0458
OG004-1.360± 2.2863
OG005-1.310± 2.2258
3
eyesOG0053
-0.080
± 0.0566
OG004-0.410± 0.7645
OG0050.873± 1.5824
2
eyesOG0053
-0.060
± 0.0529
OG004-2.255± 3.0335
OG005-2.960± 5.0319
3
eyesOG0052
-0.095
± 0.0495
OG004-0.407± 0.7778
OG005-0.040± 0.0566
3
eyesOG0052
-0.070
± 0.0624
OG004-4.847± 8.1176
OG005-0.055± 0.0778
3
eyesOG0052
-0.120
± 0.0424
OG004-0.983± 1.7747
OG005-0.050± 0.0707
3
eyesOG0053
-0.063
± 0.0551
OG004-5.640± 9.4830
OG005-2.960± 5.0664
3
eyesOG0052
-0.120
± 0.0141
OG004-1.100± 1.9504
OG005-0.050± 0.0707
3
eyesOG0053
-0.053
± 0.0551
OG004-5.623± 9.4975
OG005-3.007± 5.1386
3
eyesOG0053
-0.120
± 0.0424
OG004-1.010± 2.0313
OG0050.997± 1.8312
3
eyesOG0053
0.027
± 0.1617
OG004-5.633± 9.4975
OG005-2.993± 5.1155
3
eyesOG0053
-0.115
± 0.0919
OG004-1.107± 2.0124
OG0050.590± 1.1364
3
eyesOG0053
0.010
± 0.1552
OG004-5.657± 9.5292
OG005-3.010± 5.1357
3
eyesOG0053
-0.150
± 0.0283
OG004-1.163± 2.0063
OG0050.367± 0.7505
3
eyesOG0053
792.00
± 300.409
OG0043341.00± 4556.473
OG005937.67± 1088.262
3
eyesOG0053
-26.33
± 24.007
OG0044556.473± 248.605
OG00588.67± 422.044
3
eyesOG0053
-56.00
± 63.640
OG004-14.00± 113.331
OG005977.33± 1814.500
3
eyesOG0053
-89.33
± 125.644
OG004-369.00± 271.070
OG005-453.33± 554.795
3
eyesOG0053
-151.00
± 15.556
OG004-19.00± 123.503
OG0051008.33± 1869.924
3
eyesOG0053
-146.67
± 129.454
OG004-1070.67± 1365.685
OG005-461.33± 553.453
3
eyesOG0052
-195.50
± 6.364
OG004-20.00± 144.503
OG005-108.50± 153.442
3
eyesOG0053
-149.00
± 131.936
OG004-1096.33± 1343.289
OG005-441.00± 505.720
3
eyesOG0052
-202.50
± 4.950
OG004-81.67± 217.721
OG005-124.00± 175.362
3
eyesOG0053
-106.33
± 132.666
OG004-1055.33± 1394.128
OG005-463.00± 537.199
3
eyesOG0053
-113.50
± 47.376
OG004-143.00± 221.007
OG0051108.00± 2145.532
3
eyesOG0053
21.67
± 332.031
OG004-1059.67± 1438.362
OG005-461.67± 530.381
3
eyesOG0053
-188.00
± 65.054
OG004-113.00± 242.736
OG0051078.67± 2094.819
3
eyesOG0053
-43.33
± 243.904
OG004-1162.00± 1352.050
OG005-465.67± 587.699
3
eyesOG0053
-254.50
± 7.778
OG004-159.67± 265.038
OG0051065.67± 2074.136
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
0
eyesOG0050
1
eyesOG0051
369.00
± NA
SD cannot be estimated for 1 participant.
OG0042816.00± NASD cannot be estimated for 1 participant.
OG0054047.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-14.00
± NA
SD cannot be estimated for 1 participant.
OG004-5.00± NASD cannot be estimated for 1 participant.
1
eyesOG0051
-18.00
± NA
SD cannot be estimated for 1 participant.
OG004-12.00± NASD cannot be estimated for 1 participant.
OG005-3.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-89.00
± NA
SD cannot be estimated for 1 participant.
OG004-104.00± NASD cannot be estimated for 1 participant.
1
eyesOG0051
-22.00
± NA
SD cannot be estimated for 1 participant.
OG004-93.00± NASD cannot be estimated for 1 participant.
OG005-21.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-93.00
± NA
SD cannot be estimated for 1 participant.
OG004-122.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-36.00
± NA
SD cannot be estimated for 1 participant.
OG004-102.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-94.00
± NA
SD cannot be estimated for 1 participant.
OG004-140.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-38.00
± NA
SD cannot be estimated for 1 participant.
OG00492.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-708.00
± NA
SD cannot be estimated for 1 participant.
1
eyesOG0050
89.00
± NA
SD cannot be estimated for 1 participant.
1
eyesOG0050
-123.00
± NA
SD cannot be estimated for 1 participant.
OG004-1278.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-11.00
± NA
SD cannot be estimated for 1 participant.
OG00465.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-125.00
± NA
SD cannot be estimated for 1 participant.
OG004-1293.00± NASD cannot be estimated for 1 participant.
1
eyesOG0050
-13.00
± NA
SD cannot be estimated for 1 participant.
OG00462.00± NASD cannot be estimated for 1 participant.